Control of the cardiovascular risk factors in patients with type 2 diabetes mellitus in China in 2023–2024
Diabetes, Obesity and Metabolism · 2026-01 · 28 (1) · 497-507
DOI: 10.1111/dom.70222 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 27.10.2025. Verfasst von Wenjia Yang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cardiovascular Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: AstraZeneca Investment (China) Co., Ltd..
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
The “Real‐World Multicenter Registry to Determine Management and Quality of Care of Patients With Type 2 Diabetes in China” (iCaReMe China) aims to generate contemporary evidence in Chinese type 2 diabetes mellitus (T2DM) patients. Materials and methods This is a prospective, observational, multicentric registry study with 19 000 subjects from 110 hospitals recruited in China. Adults diagnosed with T2D and/or hypertension (HTN) (combined chronic kidney disease [CKD]), and/or heart failure (HF) and/or CKD were included. Data were collected every 6 months.
Results
In this article, we reported the findings from the baseline T2DM cohort, comprising 9000 patients recruited from 60 hospitals. The mean HbA1c level was 8.5 ± 2.2%, with 29.0% of them achieving the target HbA1c goal of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
- Department of Endocrinology, Xi'an International Medical Center Hospital, Xi'an, China.
- Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.
- Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China.
- Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- Department of Endocrinology, Shanghai East Hospital, Tongji University, Shanghai, China.
ORCID-Profile: Wenjia Yang, Xiaoling Cai, Qiuhe Ji, NanWei Tong, Ming Liu, Yanbing Li, Linong Ji
Förderung
- AstraZeneca Investment (China) Co., Ltd.
Zitieren
APA
Yang, W., Cai, X., Ji, Q., Tong, N., Liu, M., Li, Y., Feng, B., Sun, N., Zhao, M., Wang, J., Shi, Y., Wang, Z., Yao, H., Bao, M., Du, X., Wang, S., Nie, L., Yan, J., Zhao, W., & Ji, L. (2026). Control of the cardiovascular risk factors in patients with type 2 diabetes mellitus in China in 2023–2024. Diabetes, Obesity and Metabolism, 28(1), 497-507. https://doi.org/10.1111/dom.70222
Vancouver
Yang W, Cai X, Ji Q, Tong N, Liu M, Li Y, et al. Control of the cardiovascular risk factors in patients with type 2 diabetes mellitus in China in 2023–2024. Diabetes, Obesity and Metabolism. 2026;28(1):497-507. doi:10.1111/dom.70222
BibTeX
@article{Yang2026,
author = {Yang, Wenjia and Cai, Xiaoling and Ji, Qiuhe and Tong, NanWei and Liu, Ming and Li, Yanbing and Feng, Bo and Sun, Ningling and Zhao, Minghui and Wang, Junfen and Shi, Yu and Wang, Zhongjing and Yao, Hebin and Bao, Mingjing and Du, Xiaomei and Wang, Su and Nie, Lin and Yan, Jingya and Zhao, Wei and Ji, Linong},
title = {Control of the cardiovascular risk factors in patients with type 2 diabetes mellitus in China in 2023–2024},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {1},
pages = {497--507},
doi = {10.1111/dom.70222}
}
EUVIMED